Titanium Media App reported on April 25 that WuXi AppTec (603259.SH / 2359.HK) released its 2022 first quarter performance report. The data shows that WuXi AppTec ’s Q1 revenue was 8.474 billion yuan, a year-on-year increase of 71.2%. The net profit of shareholders of listed companies was 1.643 billion yuan, a year-on-year increase of 9.5%. In the first quarter, WuXi PharmaTech’s chemical business achieved revenue of 6.118 billion yuan, a year-on-year increase of 102.1%; the testing business achieved revenue of 1.279 billion yuan, a year-on-year increase of 31.7%; the biology business achieved revenue of 533 million yuan, a year-on-year increase of 26.2%; cell and gene therapy The CTDMO business achieved revenue of 299 million yuan, a year-on-year increase of 37.0%; the domestic new drug research and development service department achieved revenue of 241 million yuan, a year-on-year decrease of 21.6%. During the reporting period, the company added more than 320 new customers, and the number of active customers exceeded 5,800.
media coverage
Titanium Media NetEase News IT Home
event tracking
- 2022-04-25WuXi AppTec’s revenue in the first quarter of 2022 was 8.474 billion yuan, a year-on-year increase of 71.2%
- 2021-04-29WuXi AppTec: Net profit of 1.5 billion yuan in the first quarter, a year-on-year increase of 394.92%
- 2020-03-24WuXi AppTec’s revenue in 2019 was 12.872 billion yuan, a year-on-year increase of 33.9%
- 2018-12-13WuXi PharmaTech was listed on the Hong Kong Stock Exchange today, raising HK$7.5 billion
- 2018-10-29WuXi AppTec: The Ministry of Science and Technology’s administrative penalty has been rectified last year
This article is reprinted from: https://readhub.cn/topic/8fvore3csPb
This site is for inclusion only, and the copyright belongs to the original author.